J Psychiatry Neurosci 2014;39(1)
Editorial
Light up your life: Optogenetics for depression?
P.R. Albert
Review Paper
Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology
S. Comai, G. Gobbi
Research Papers
Abnormal interhemispheric connectivity in male psychopathic offenders
S.S. Hoppenbrouwers, D.R. De Jesus, Y. Sun, T. Stirpe, D. Hofman, J. McMaster, G. Hughes, Z.J. Daskalakis, D.J.L.G. Schutter
Association of a risk allele of ANK3 with cognitive performance and cortical thickness in patients with first-episode psychosis
C. Cassidy, L. Buchy, M. Bodnar, J. Dell’Elce, Z. Choudhry, F. Fathalli, S. Sengupta, R. Fox, A. Malla, M. Lepage, S. Iyer, R. Joober
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
D. Bakish, A. Bose, C. Gommoll, C. Chen, R. Nunez, W.M. Greenberg, M. Liebowitz, A. Khan
Effect of childhood maltreatment on brain structure in adult patients with major depressive disorder and healthy participants
A. Chaney, A. Carballedo, F. Amico, A. Fagan, N. Skokauskas, J. Meaney, T. Frodl
Cerebellar motor learning deficits in medicated and medication-free men with recent-onset schizophrenia
M. Coesmans, C.H. Röder, A.E. Smit, S.K.E. Koekkoek, C.I. De Zeeuw, M.A. Frens, J.N. van der Geest
Commentary
Possible role of more positive social behaviour in the clinical effect of antidepressant drugs
S.N. Young, D.S. Moskowitz, M. aan het Rot
Reviewers
Psychopharmacology for the Clinician
Off-label antipsychotic use and tardive dyskinesia in at-risk populations: new drugs with old side effects
G. Remington, M. Hahn